Dynavax Technologies Corporation [NASDAQ: DVAX] price plunged by -1.96 percent to reach at -$0.13. The company report on August 13, 2020 that Dynavax Announces Grant to Scale up CpG 1018 Adjuvant Capacity to Support the Global COVID-19 Response.
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a grant from the Bill & Melinda Gates Foundation of $3.4 million to scale up production batch size to allow for increased capacity of Dynavax’s CpG 1018 advanced adjuvant to support the global COVID-19 response. These efforts will support capacity of up to 750 million adjuvant doses annually, which can be further increased if needed.
“We are honored to receive this funding from the Bill & Melinda Gates Foundation to support development of a much-needed vaccine for COVID-19. This grant facilitates scale up of production capacity to ensure the availability of CpG 1018 for collaboration partners developing adjuvanted vaccines for COVID-19,” commented Ryan Spencer, Chief Executive Officer of Dynavax. “We believe adjuvants will play an important role in developing effective vaccines for COVID-19, including for those patients at greatest risk for severe disease. The ability of CpG 1018 to potentially provide an improved immune response and also reduce the amount of vaccine antigen necessary will help provide more vaccine doses to meet the global need.”.
A sum of 2418407 shares traded at recent session while its average daily volume was at 8.01M shares. Dynavax Technologies Corporation shares reached a high of $6.66 and dropped to a low of $6.46 until finishing in the latest session at $6.49.
Guru’s Opinion on Dynavax Technologies Corporation [DVAX]:
H.C. Wainwright have made an estimate for Dynavax Technologies Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 07, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $12 to $14. The new note on the price target was released on August 03, 2020, representing the official price target for Dynavax Technologies Corporation stock. Previously, the target price had yet another raise to $14, while Evercore ISI analysts kept a Outperform rating on DVAX stock.
The Average True Range (ATR) for Dynavax Technologies Corporation is set at 0.82, with the Price to Sales ratio for DVAX stock in the period of the last 12 months amounting to 20.76. The Price to Book ratio for the last quarter was 10.82, with the Price to Cash per share for the same quarter was set at 1.81.
DVAX Stock Performance Analysis:
Dynavax Technologies Corporation [DVAX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.81. With this latest performance, DVAX shares dropped by -36.50% in over the last four-week period, additionally plugging by 32.18% over the last 6 months – not to mention a rise of 48.51% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DVAX stock in for the last two-week period is set at 37.63, with the RSI for the last a single of trading hit 29.87, and the three-weeks RSI is set at 41.16 for Dynavax Technologies Corporation [DVAX]. The present Moving Average for the last 50 days of trading for this stock 8.13, while it was recorded at 6.75 for the last single week of trading, and 5.73 for the last 200 days.
Insight into Dynavax Technologies Corporation Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Dynavax Technologies Corporation [DVAX] shares currently have an operating margin of -338.44 and a Gross Margin at +27.47. Dynavax Technologies Corporation’s Net Margin is presently recorded at -433.29.
Return on Total Capital for DVAX is now -60.86, given the latest momentum, and Return on Invested Capital for the company is -78.52. Return on Equity for this stock declined to -427.72, with Return on Assets sitting at -62.29. When it comes to the capital structure of this company, Dynavax Technologies Corporation [DVAX] has a Total Debt to Total Equity ratio set at 2,647.59. Additionally, DVAX Total Debt to Total Capital is recorded at 96.36, with Total Debt to Total Assets ending up at 78.65. Long-Term Debt to Equity for the company is recorded at 2,610.93, with the Long-Term Debt to Total Capital now at 95.03.
Reflecting on the efficiency of the workforce at the company, Dynavax Technologies Corporation [DVAX] managed to generate an average of -$660,606 per employee. Receivables Turnover for the company is 5.59 with a Total Asset Turnover recorded at a value of 0.14.Dynavax Technologies Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.00 and a Current Ratio set at 5.00.
DVAX Stock EPS
With the latest financial reports released by the company, Dynavax Technologies Corporation posted -0.49/share EPS, while the average EPS was predicted by analysts to be reported at -0.39/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -25.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DVAX.
Dynavax Technologies Corporation [DVAX] Insider Position Details
There are presently around $524 million, or 60.90% of DVAX stock, in the hands of institutional investors. The top three institutional holders of DVAX stocks are: FEDERATED HERMES, INC. with ownership of 11,166,800, which is approximately 14.334% of the company’s market cap and around 0.40% of the total institutional ownership; BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, holding 10,895,773 shares of the stock with an approximate value of $70.71 million in DVAX stocks shares; and BLACKROCK INC., currently with $45.25 million in DVAX stock with ownership of nearly 16.872% of the company’s market capitalization.
Positions in Dynavax Technologies Corporation stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 99 institutional holders increased their position in Dynavax Technologies Corporation [NASDAQ:DVAX] by around 22,790,109 shares. Additionally, 40 investors decreased positions by around 7,814,587 shares, while 23 investors held positions by with 50,115,713 shares. The mentioned changes placed institutional holdings at 80,720,409 shares, according to the latest SEC report filing. DVAX stock had 47 new institutional investments in for a total of 9,683,557 shares, while 15 institutional investors sold positions of 1,588,724 shares during the same period.